ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Pfizer and Innovent Biologics side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

PfizerInnovent Biologics
studies on the registry4,073218
open to participants now14759
phase 3 studies under way9923
reach primary completion within a year9236
programswith a study of their own in two years91+9 named only40

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phasePfizerInnovent Biologics
Phase 1

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Innovent Biologics: 14 of its 40 programs at phase 1

  1. IBI3033phase 1
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. Anti-CEACAM5 Antibody-drug Conjugate IBI3020phase 1
  5. IBI115phase 1

and 9 more — sign in to see them all

35%
Phase 2

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%

Innovent Biologics: 10 of its 40 programs at phase 2

  1. IBI3016phase 2
  2. telitaciceptphase 2
  3. IBI355phase 2
  4. IBI3002phase 2
  5. IBI3011phase 2

and 5 more — sign in to see them all

25%
Phase 3

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%
38%
Approved, new studies

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Innovent Biologics: 1 of its 40 programs at approved, new studies

  1. Teprotumumab N01approved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Innovent Biologics18 readouts · 4 phase 3

Innovent Biologics, Nov ’26: 1 program whose next study reaches primary completion

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3 · Nov 30 · NCT07122687

Innovent Biologics, Dec ’26: 6 programs whose next study reaches primary completion, 3 in phase 3

  1. arcotatug tavatecanphase 3 · Dec 30 · NCT06238843
  2. GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003phase 3 · Dec 31 · NCT07764861
  3. IBI302phase 3 · Dec 31 · NCT06908876
  4. IBI3026early phase 1 · Dec 31 · NCT07327632
  5. IBI311phase 3 · Dec 31 · NCT07113262

and 1 more — sign in to see them all

Innovent Biologics, Jan ’27: 3 programs whose next study reaches primary completion

  1. IBI3016phase 2 · Jan 30 · NCT07838220
  2. IBI3034phase 1 · Jan 31 · NCT07886476
  3. telitaciceptphase 2 · Jan 31 · NCT07886476

Innovent Biologics, Feb ’27: 1 program whose next study reaches primary completion

  1. IBI3033phase 1 · Feb 10 · NCT07549984

Innovent Biologics, Mar ’27: 2 programs whose next study reaches primary completion

  1. IBI3042phase 1 · Mar 2 · NCT07842393
  2. IBI3002phase 2 · Mar 23 · NCT07399067

Innovent Biologics, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tigulixostatphase 3 · Apr 30 · NCT07414394

Innovent Biologics, May ’27: 1 program whose next study reaches primary completion

  1. IBI3011phase 2 · May 11 · NCT07842497

Innovent Biologics, Jun ’27: 2 programs whose next study reaches primary completion

  1. IBI3031phase 1 · Jun 15 · NCT07622368
  2. IBI3028phase 1 · Jun 30 · NCT07589205

Innovent Biologics, Jul ’27: 1 program whose next study reaches primary completion

  1. IBI3035phase 1 · Jul 30 · NCT07591519
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 7

Innovent Biologics

New programs 4

  • IBI3043phase 1 · first study · Oct 22
  • IBI3034phase 1 · first study · Oct 8 · Glomerulonephritis, IGA
  • telitaciceptphase 2 · first study · Sep 13 · Lupus Erythematosus, Systemic
  • IBI3046phase 1 · first study · Sep 3 · Obesity

Reached a new phase 2

  • IBI3011phase 2 · Sep 14 · Gout
  • IBI355phase 2 · Sep 13 · Sjogren's Syndrome

Study stopped 1

  • IBI356phase 2 · terminated Oct 27 · none of its studies left running“Sponsor Decision” · NCT07330934

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 19 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionPfizerInnovent Biologics
Carcinoma, Non-Small-Cell Lungboth · compare here

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Innovent Biologics in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3
  2. sintilimabphase 3
  3. gimeracilphase 2
  4. Oxonic Acidphase 2
  5. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Carcinoma, Non-Small-Cell Lung in search

Dermatitis, Atopicboth · compare here

Pfizer in Dermatitis, Atopic: 7 programs

  1. tilrekimigphase 3
  2. abrocitinibphase 3
  3. etrasimodphase 3
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Dermatitis, Atopic in search

Innovent Biologics in Dermatitis, Atopic: 4 programs

  1. IBI3027phase 3
  2. IBI3002phase 2
  3. IBI356phase 2
  4. IBI3033phase 1

Their studies: Innovent Biologics’ studies of Dermatitis, Atopic in search

Obesityboth · compare here

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

Innovent Biologics in Obesity: 4 programs

  1. mazdutidephase 3
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. IBI3046phase 1

Their studies: Innovent Biologics’ studies of Obesity in search

Colorectal Neoplasmsboth · compare here

Pfizer in Colorectal Neoplasms: 4 programs

  1. tivunatamigphase 3
  2. tusamitamab sonditecanphase 1
  3. tucatinibapproved, new study
  4. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Colorectal Neoplasms in search

Breast Neoplasmsboth · compare here

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Innovent Biologics in Breast Neoplasms: 1 program

  1. Anti-HER2 Antibody-drug Conjugate IBI354phase 3

Their studies: Innovent Biologics’ studies of Breast Neoplasms in search

Renal Insufficiencyboth · compare here

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Innovent Biologics in Renal Insufficiency: 3 programs

  1. gimeracilphase 2
  2. Oxonic Acidphase 2
  3. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Renal Insufficiency in search

Melanomaboth · compare here
Stomach Neoplasmsboth · compare here

Pfizer in Stomach Neoplasms: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Innovent Biologics in Stomach Neoplasms: 4 programs

  1. sintilimabphase 3
  2. gimeracilphase 2
  3. Oxonic Acidphase 2
  4. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Stomach Neoplasms in search

Asthmaboth · compare here

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Innovent Biologics in Asthma: 1 program

  1. IBI3002phase 2

Their studies: Innovent Biologics’ studies of Asthma in search

Small Cell Lung Carcinomaboth · compare here

Pfizer in Small Cell Lung Carcinoma: 3 programs

  1. tivunatamigphase 3
  2. mevrometostatphase 3
  3. tegtociclibphase 2

Their studies: Pfizer’s studies of Small Cell Lung Carcinoma in search

Innovent Biologics in Small Cell Lung Carcinoma: 1 program

  1. IBI115phase 1

Their studies: Innovent Biologics’ studies of Small Cell Lung Carcinoma in search

Alopecia Areataboth · compare here

Pfizer in Alopecia Areata: 2 programs

  1. ritlecitinibphase 3
  2. etrasimodphase 3

Their studies: Pfizer’s studies of Alopecia Areata in search

Innovent Biologics in Alopecia Areata: 1 program

  1. IBI3013phase 1

Their studies: Innovent Biologics’ studies of Alopecia Areata in search

Colitis, Ulcerativeboth · compare here

Pfizer in Colitis, Ulcerative: 2 programs

  1. etrasimodphase 3
  2. PF-07054894phase 1

Their studies: Pfizer’s studies of Colitis, Ulcerative in search

Innovent Biologics in Colitis, Ulcerative: 1 program

  1. IBI112phase 3

Their studies: Innovent Biologics’ studies of Colitis, Ulcerative in search

Show all 19

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Pfizer 67 of 91 · Innovent Biologics 16 of 40 programs (33 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Pfizer: 9).